These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35459391)

  • 41. [Secondary osteoporosis. Disordered bone metabolism in chronic kidney disease.].
    Nakagawa Y; Komaba H
    Clin Calcium; 2018; 28(12):1611-1618. PubMed ID: 30487325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Vitamin D metabolism and chronic kidney disease].
    Honda H; Sanada D; Akizawa T
    Clin Calcium; 2006 Jul; 16(7):1143-46. PubMed ID: 16816474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.
    Lundquist AL; Nigwekar SU
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):120-6. PubMed ID: 26785065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Ultrasonography methods in the diagnosis of renal osteodystrophy].
    Tomić-Brzac H; Pavlović D
    Acta Med Croatica; 2004; 58(1):43-9. PubMed ID: 15125393
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secondary hyperparathyroidism in chronic renal failure.
    Wills MR; Savory J
    Ann Clin Lab Sci; 1981; 11(3):252-61. PubMed ID: 6264838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changing Spectrum of Mineral Bone Disorder in Chronic kidney disease stage 3 to 5 D and Its Associated Factors, A Prospective Cross-Sectional Study from Tertiary Care Hospital in Northern India.
    Sethi S; Sethi N; Sandhu JS; Makkar V; Kaur S; Sohal PM; Mehta S
    Iran J Kidney Dis; 2021 May; 15(3):199-205. PubMed ID: 33994379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term management of CKD-mineral and bone disorder.
    Martin KJ; González EA
    Am J Kidney Dis; 2012 Aug; 60(2):308-15. PubMed ID: 22520454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications.
    Salanova Villanueva L; Sánchez González C; Sánchez Tomero JA; Aguilera A; Ortega Junco E
    Nefrologia; 2016; 36(4):368-75. PubMed ID: 27118192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secondary hyperparathyroidism in chronic renal failure. Pathophysiology and treatment.
    Hanley DA; Sherwood LM
    Med Clin North Am; 1978 Nov; 62(6):1319-39. PubMed ID: 368449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study.
    Yun HJ; Ryoo SR; Kim JE; Choi YJ; Park I; Shin GT; Kim H; Jeong JC
    BMC Nephrol; 2020 Jul; 21(1):299. PubMed ID: 32711466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Research on kidney and mineral metabolism in Japan: past, present, and future.
    Mizobuchi M; Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):4-8. PubMed ID: 28005175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis and treatment of Sagliker syndrome: a case series from Iran.
    Mohebi-Nejad A; Gatmiri SM; Abooturabi SM; Hemayati R; Mahdavi-Mazdeh M
    Iran J Kidney Dis; 2014 Jan; 8(1):76-80. PubMed ID: 24413727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
    Pazianas M; Miller PD
    J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cellular-level bone resorption in chronic renal failure and primary hyperparathyroidism. A tetracycline-based evaluation.
    Villanueva AR; Jaworski ZF; Hitt O; Sarnsethsiri P; Frost HM
    Calcif Tissue Res; 1970; 5(4):288-304. PubMed ID: 5469609
    [No Abstract]   [Full Text] [Related]  

  • 57. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uremic Toxicity and Bone in CKD.
    Yamamoto S; Fukagawa M
    J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.